In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

You might receive this kind of adjuvant therapy for several years after initial treatment. For example, with some types of breast cancer, the hormone estrogen causes cancer cells with estrogen ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

Slamon said that currently approved targeted treatments “can only be ... to show activity in adjuvant early breast cancer in the PALLAS and PENELOPE trials. Novartis has said it intends to ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral medications like trastuzumab deruxtecan (Enhertu) and pembrolizumab (Keytruda), ...

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.